Campbell & CO Investment Adviser LLC Raises Stock Holdings in Glaukos Corporation $GKOS

Key Points

• Campbell & CO Investment Adviser LLC increased its stake in Glaukos Corporation by 89.8%, owning a total of 13,877 shares valued at $1.37 million after acquiring an additional 6,566 shares in the first quarter.
• Glaukos reported a revenue of $124.12 million for the last quarter, surpassing analyst expectations, with a year-over-year increase of 29.7%.
• The stock currently has an average rating of "Moderate Buy" from analysts, with a price target averaging $127.42.

Campbell & CO Investment Adviser LLC raised its holdings in Glaukos Corporation (NYSE:GKOS - Free Report) by 89.8% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 13,877 shares of the medical instruments supplier's stock after acquiring an additional 6,566 shares during the quarter. Campbell & CO Investment Adviser LLC's holdings in Glaukos were worth $1,366,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Wellington Management Group LLP lifted its position in shares of Glaukos by 6.1% in the 1st quarter. Wellington Management Group LLP now owns 2,290,790 shares of the medical instruments supplier's stock worth $225,460,000 after purchasing an additional 131,251 shares during the period. Primecap Management Co. CA lifted its position in shares of Glaukos by 0.3% in the 1st quarter. Primecap Management Co. CA now owns 1,218,475 shares of the medical instruments supplier's stock worth $119,922,000 after purchasing an additional 4,150 shares during the period. Westfield Capital Management Co. LP lifted its position in shares of Glaukos by 34.3% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,084,184 shares of the medical instruments supplier's stock worth $106,705,000 after purchasing an additional 277,033 shares during the period. Northern Trust Corp lifted its position in shares of Glaukos by 7.4% in the 4th quarter. Northern Trust Corp now owns 578,673 shares of the medical instruments supplier's stock worth $86,766,000 after purchasing an additional 40,052 shares during the period. Finally, Principal Financial Group Inc. lifted its position in shares of Glaukos by 21.8% in the 1st quarter. Principal Financial Group Inc. now owns 327,036 shares of the medical instruments supplier's stock worth $32,187,000 after purchasing an additional 58,502 shares during the period. Institutional investors and hedge funds own 99.04% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on GKOS shares. Mizuho set a $130.00 price target on shares of Glaukos in a research report on Thursday, July 31st. BTIG Research restated a "buy" rating on shares of Glaukos in a research report on Monday, July 14th. Morgan Stanley reduced their price objective on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Wells Fargo & Company raised their price objective on shares of Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Finally, Zacks Research downgraded shares of Glaukos from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Glaukos has an average rating of "Moderate Buy" and an average price target of $127.42.

Glaukos Trading Down 0.7%

Shares of GKOS stock traded down $0.70 during trading hours on Monday, hitting $95.86. 488,453 shares of the company were exchanged, compared to its average volume of 795,239. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. Glaukos Corporation has a fifty-two week low of $77.10 and a fifty-two week high of $163.71. The company has a 50 day simple moving average of $95.60 and a two-hundred day simple moving average of $98.45. The firm has a market cap of $5.50 billion, a P/E ratio of -58.10 and a beta of 0.77.

Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The company had revenue of $124.12 million for the quarter, compared to analyst estimates of $115.49 million. During the same period in the prior year, the firm earned ($0.52) earnings per share. Glaukos's revenue for the quarter was up 29.7% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. Equities analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.